(WASHINGTON) -- The Food and Drug Administration has granted wider use of a drug for juvenile arthritis. Actemra was approved to treat children aged two years or older with active systemic juvenile idiopathic arthritis (SJIA), a rare illness for children.
The drug, made by Roche Holding AG, was approved last year as a treatment for adult arthritis patients for who don't receive an adequate response from other medications.
According to the FDA, SJIA is a potentially life-threatening illness that causes inflammation throughout the entire body.
Copyright 2011 ABC News Radio